Quantitative detection method for components of eight-component kidney-tonifying capsules

The UPLC-QQQ-MS method addresses the quality control challenges of Bazi Bushen Capsule by precisely quantifying its 17 components, enhancing the quality control and efficacy of the traditional Chinese medicine.

CN119086759APending Publication Date: 2024-12-06SHIJIAZHUANG YILING PHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411263437.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-10
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The complexity of chemical composition and ambiguity of pharmacological substances in traditional Chinese medicine hinder the quality control of Bazi Bushen Capsule, a compound composed of 16 single herbs, which affects its clinical efficacy and modernization.

Method used

A quantitative detection method using UPLC-QQQ-MS to determine the contents of 17 components in Bazi Bushen Capsule, employing chromatography and mass spectrometry with specific conditions for chromatographic and mass spectrometric analysis.

Benefits of technology

The method achieves precise and reproducible quantification of 17 components with high precision and stability, ensuring good reproducibility and accuracy, suitable for quality control of Bazi Bushen Capsule.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005036460900000081
    Figure BDA0005036460900000081
  • Figure BDA0005036460900000091
    Figure BDA0005036460900000091
  • Figure BDA0005036460900000092
    Figure BDA0005036460900000092
Patent Text Reader

Abstract

The invention relates to the field of traditional Chinese medicine detection, in particular to a quantitative detection method for components of eight-component kidney-tonifying capsules. According to the invention, UPLC-QQQ-MS is adopted to determine the contents of 17 components in the eight-component kidney-tonifying capsules in 10 batches. The invention also verifies the precision, repeatability and stability of the quantitative method for 17 components. The intra-day precision and the inter-day precision are expressed by RSD (Relative Standard Deviation), and the ranges are 0.1-2.7% and 1.5-3.8% respectively The repeatability and the stability are not more than 4.9% and 7.0% respectively. Therefore, the established method has good reproducibility, precision and stability. The average recovery rate is 91.7%-106.8%, and the RSD (Relative Standard Deviation) is less than 9.0%. The method established by the invention is suitable for quantitative analysis of 17 components in the eight-component kidney-tonifying capsule, and has guiding significance for subsequent research of the eight-component kidney-tonifying capsule.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of traditional Chinese medicine detection, and in particular to a quantitative detection method for components of Bazi Bushen Capsule. Background Art

[0002] Traditional Chinese medicine plays an important role in the prevention and treatment of diseases, and therefore has received increasing attention and recognition worldwide. The quality of traditional Chinese medicine directly affects the clinical efficacy and restricts the development of modernization of traditional Chinese medicine. However, the complexity of chemical composition and the ambiguity of pharmacological substances are huge obstacles to the quality control of traditional Chinese medicine. In the process of strategy exploration, Liu et al. proposed the concept of quality markers. This concept focuses on the measurability, specificity, transferability, effectiveness and traceability of quality markers of traditional Chinese medicine. The characterization of quality markers involves the integration of multiple properties, including component analysis, content determination, pharmacokinetics, network pharmacology, etc. There are a variety of plant secondary metabolites in traditional Chinese medicine, and components with different structures may have different biological activities. Therefore, the quality markers of traditional Chinese medicine need to consider the different structural types of different components, which is of great significance for the quality control of traditional Chinese medicine based on traditional efficacy. In addition, network pharmacology is increasingly being used to reveal the mechanism of action between active ingredients and disease therapeutic targets. At present, the use of network pharmacology to screen quality markers is mainly based on the degree of association between a single compound and a disease target, and the mode of action of multiple components of traditional Chinese medicine covering multiple targets in the form of a combination to exert pharmacological effects is not prominent. In addition, the metabolism of TCM ingredients in the body will lead to changes in their biological activity, and the in vivo process of TCM ingredients is also particularly important for determining the quality markers of TCM. It is well known that TCM prescriptions have the characteristics of multi-component, multi-target, and overall regulation, but there are currently few reports on mining TCM quality markers from a holistic perspective. Therefore, this study proposed a digital and holistic strategy to mine the quality markers of absorbable ingredients in Bazi Bushen Capsule in the form of different compositions to reflect the structural diversity and diversity of biological pathways.

[0003] Bazi Bushen Capsule (BZBS) is a traditional Chinese medicine compound, which is composed of 16 single herbs, including Cuscuta, Lycium, Schisandra, Cnidium, Rosa Laevigata, Rubus, Toosendan, Allium, Epimedium, Morinda, Cistanche, Rehmannia, Cyathula, Ginseng, Pilose Antler, and Hippocampus. It is clinically used to prevent and treat symptoms such as soreness of waist and knees, dizziness, tinnitus, and fatigue caused by insufficient kidney yang. Recent pharmacological studies have shown that Bazi Bushen Capsule can significantly improve the bone morphology of aged mice induced by D-galactose and NaNO2, and increase the mineral content in their bone tissue. In addition, Bazi Bushen Capsule can also improve the bone microstructure of the distal tibia in ovariectomized osteoporosis rats. A large number of literature reports show that a variety of single herbs in Bazi Bushen Capsule, such as Cuscuta, Lycium barbarum, Cnidium monnieri, Epimedium, Ginseng, Cistanche deserticola and Rehmannia root, can improve the bone microstructure parameters of ovariectomized osteoporosis model rats / mice. In summary, Bazi Bushen Capsule has a significant anti-osteoporosis effect. Bazi Bushen Capsule has a definite efficacy, but the quality control research of Bazi Bushen Capsule is seriously insufficient. Therefore, it is urgent to find the quality markers of Bazi Bushen Capsule to improve its quality control level.

[0004] It is worth noting that Bazibushen Capsule is a complex system composed of 16 single herbs, and the content determination of its ingredients has not been reported, which seriously hinders the quality control research of Bazibushen Capsule. Summary of the invention

[0005] In view of this, the present invention provides a quantitative detection method for the components of Bazi Bushen Capsule. The present invention uses UPLC-QQQ-MS to determine the contents of 17 components in 10 batches of Bazi Bushen Capsule.

[0006] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0007] The present invention provides a quantitative detection method for the components of Bazi Bushen Capsule, comprising the following steps:

[0008] Take the contents of Bazi Bushen Capsule to prepare sample solution;

[0009] Take the standard sample to prepare the standard solution;

[0010] The sample solution and the standard solution were respectively taken for UPLC-QQQ-MS detection to determine the content of the ingredients in the Bazi Bushen Capsule.

[0011] In some specific embodiments of the present invention, the detection comprises chromatography and mass spectrometry;

[0012] The mobile phase of the chromatographic analysis includes: A is a 0.1% (v / v) formic acid solution, and B is a 0.1% (v / v) formic acid acetonitrile solution.

[0013] In some specific embodiments of the present invention, the flow rate of the chromatography analysis is 0.3 ml / min; and / or

[0014] The injection volume of the chromatographic analysis was 2 μL.

[0015] In some specific embodiments of the present invention, the gradient elution conditions of the chromatographic analysis are: 0-2.5 min, 2-15% B; 2.5-6.5 min, 15-36% B; 6.5-12.5 min, 36-75% B; 12.5-14 min, 75-100% B; 14-15 min, 100% B; 15-16 min, 100%-2% B; 16-17 min 2% B.

[0016] In some specific embodiments of the present invention, the chromatographic analysis uses Acquity UPLC HSS T3 column (2.1×50 mm, 1.8 μm), and the temperature of the chromatographic column is 35° C.

[0017] In some specific embodiments of the present invention, the mass spectrometry analysis uses an electrospray ion source (ESI), positive and negative ion mode detection, the acquisition method is FastDDA, the scanning range is m / z 50-1500Da, and the capillary spray voltage ion is 2.0kV (ESI+) and 2.0kV (ESI-).

[0018] In some specific embodiments of the present invention, the source temperature of the mass spectrometry analysis is 150°C, the desolvation gas temperature is 550°C, the desolvation gas flow rate is 1000L / h, the cone gas flow rate is 150L / h, and the analytes are detected using positive and negative multiple reaction monitoring (MRM) mode.

[0019] In some specific embodiments of the present invention, the sample solution is prepared by: dissolving the contents of the Bazi Bushen Capsule with methanol, ultrasonically extracting, centrifuging, filtering, and collecting the supernatant to obtain the sample solution;

[0020] The preparation method of the standard solution is: taking the standard, dissolving and diluting it with methanol to obtain the standard solutions of different concentrations.

[0021] In some specific embodiments of the present invention, the sample solution is prepared by taking the contents of the Bazi Bushen Capsule, dissolving and extracting it with 70% methanol solution, ultrasonically treating it for 30 minutes, centrifuging it at 13200 rpm for 10 minutes, filtering it, and collecting the supernatant.

[0022] In some specific embodiments of the present invention, the ingredients of the Ba Zi Bushen Capsule include Hyperin, Osthole, Imperatorin, Isopimpinellin, Xanthotoxin, Icaritin, Icariin, Epimedin C, Magnoflorine, Rutin, Schisantherin B, Schisandrin, Schisantherin A, Schisandrin B, 19α-Hydroxyasiatic acid, cariside II, and Cuscutamine;

[0023] The ingredient contents of the Bazi Bushen Capsule are shown in Table 7.

[0024] The present invention uses UPLC-QQQ-MS to determine the contents of 17 components in 10 batches of Bazi Bushen Capsules. The linear correlation coefficients (R2) of the calibration curves of the 17 components calculated by the present invention are all greater than 0.99 (external standard method). The present invention also verifies the precision, repeatability and stability of the quantitative method of the 17 components. The intra-day and inter-day precisions are represented by RSD, and the ranges are 0.1-2.7% and 1.5-3.8%, respectively. The repeatability and stability do not exceed 4.9% and 7.0%, respectively. Therefore, the established method has good reproducibility, precision and stability. The average recovery rate is 91.7%-106.8%, and the RSD is less than 9.0%. The method established by the present invention is suitable for the quantitative analysis of 17 components in Bazi Bushen Capsules, and has guiding significance for the subsequent research of Bazi Bushen Capsules. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art are briefly introduced below.

[0026] Figure 1 The MRM diagram of hyperoside in 17 quantitative components is shown; A: Bazi Bushen Capsule test solution; B: mixed reference substance; C: blank solvent;

[0027] Figure 2 The MRM diagram of osthole in 17 quantitative components is shown; A: Bazi Bushen Capsule test solution; B: mixed reference substance; C: blank solvent;

[0028] Figure 3The MRM diagram of imperatorin in 17 quantitative components is shown; A: Bazi Bushen Capsule test solution; B: mixed reference substance; C: blank solvent;

[0029] Figure 4 The MRM diagram of isosaxifragein in 17 quantitative components is shown; A: Bazi Bushen Capsule test solution; B: mixed reference substance; C: blank solvent;

[0030] Figure 5 The MRM diagram of Zanthoxylum bungeanum toxin in 17 quantitative components is shown; A: Bazi Bushen Capsule test solution; B: mixed reference substance; C: blank solvent;

[0031] Figure 6 The MRM diagram of icariin in 17 quantitative components is shown; A: Bazi Bushen Capsule test solution; B: mixed reference substance; C: blank solvent;

[0032] Figure 7 The MRM diagram of icariin in 17 quantitative components is shown; A: Bazi Bushen Capsule test solution; B: mixed reference substance; C: blank solvent;

[0033] Figure 8 The CMRM diagram of Epimedium among the 17 quantitative components is shown; A: Bazi Bushen Capsule test solution; B: mixed reference substance; C: blank solvent;

[0034] Fig. 9 The MRM diagram of magnolia alkaloids in 17 quantitative components is shown; A: Bazi Bushen Capsule test solution; B: mixed reference substance; C: blank solvent;

[0035] Fig.10 The MRM diagram of rutin in 17 quantitative components is shown; A: Bazi Bushen Capsule test solution; B: mixed reference substance; C: blank solvent;

[0036] Fig.11 The MRM diagram of Schisandrae Chinensis Ester B in 17 quantitative components is shown; A: Bazi Bushen Capsule test solution; B: mixed reference substance; C: blank solvent;

[0037] Fig.12 The MRM diagram of Schisandrin A in 17 quantitative components is shown; A: Bazi Bushen Capsule test solution; B: mixed reference substance; C: blank solvent;

[0038] Fig.13 The MRM diagram of Schisandrae Chinensis ester A in 17 quantitative components is shown; A: Bazi Bushen Capsule test solution; B: mixed reference substance; C: blank solvent;

[0039] Fig.14The MRM diagram of Schisandrin B in 17 quantitative components is shown; A: Bazi Bushen Capsule test solution; B: mixed reference substance; C: blank solvent;

[0040] Fig.15 The MRM diagram of 23-caryophyllene acid in 17 quantitative components is shown; A: Bazi Bushen Capsule test solution; B: mixed reference substance; C: blank solvent;

[0041] Fig.16 The IIMRM graph of icariin in 17 quantitative components is shown; A: Bazi Bushen Capsule test solution; B: mixed reference substance; C: blank solvent;

[0042] Fig.17 The MRM diagram of dodderine in 17 quantitative components is shown; wherein, A: Bazi Bushen Capsule test solution; B: mixed reference substance; C: blank solvent. DETAILED DESCRIPTION

[0043] The present invention discloses a quantitative detection method for the ingredients of Bazi Bushen Capsule. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters to achieve it. It should be particularly noted that all similar substitutions and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The method and application of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications described herein without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.

[0044] The 17 ingredients of Bazi Bushen Capsule were quantitatively analyzed based on ultra-high performance liquid chromatography-triple quadrupole tandem mass spectrometry (UPLC-QQQ-MS). The chromatogram was adjusted as follows:

[0045] Chromatograph: Waters Acquity UPLC I-Class

[0046] Chromatographic column: Acquity UPLC HSS T3 column (2.1×50 mm, 1.8 μm);

[0047] Column temperature: 35°C;

[0048] Mobile phase: A is 0.1% (v / v) formic acid solution, B is 0.1% (v / v) formic acid acetonitrile solution;

[0049] Flow rate: 0.3ml / min;

[0050] Injection volume: 2 μL;

[0051] Gradient elution conditions: 0-2.5min, 2-15% B; 2.5-6.5min, 15-36% B; 6.5-12.5min, 36-75% B; 12.5-14min, 75-100% B; 14-15min, 100% B; 15-16min, 100%-2% B; 16-17min2% B;

[0052] Mass spectrometer: Waters Xevo Triple Quadrupole mass spectrometer

[0053] Mass spectrometry conditions: electrospray ion source (ESI), positive and negative ion mode detection; capillary spray voltage ion 2.0 kV (ESI+) and 2.0 kV (ESI-); source temperature 150 ° C; desolvation temperature 550 ° C; desolvation gas flow rate 1000 L / h, cone gas flow rate 150 L / h, positive and negative multiple reaction monitoring (MRM) mode was used to detect the analytes;

[0054] Sample solution preparation: 0.5 g of the contents of Bazi Bushen Capsule were extracted with 70% methanol solution for 30 min by ultrasonic method to obtain a sample solution with a concentration of 100 μg / ml. The sample solution was centrifuged at 13200 rpm for 10 min, filtered, and the supernatant was used as the injection solution;

[0055] Preparation of standard solution: Accurately measure the reference substance and dissolve it with methanol to obtain a solution with a concentration of 100 μg / ml; dilute it with methanol in different 10 ml volumetric flasks to obtain mixed standard solutions of different concentrations.

[0056] Experimental Materials:

[0057] Cuscuta, Lycium, Schisandra, Cnidium, Rosa laevigata, Rubus idaeus, Toosendan, Allium, Epimedium, Morinda officinalis, Cistanche, Rehmannia, Cyathula, Ginseng, Pilose antler, Hippocampus and 10 batches of Bazi Bushen Capsules were provided by Shijiazhuang Yiling Pharmaceutical Co., Ltd., China.

[0058] Monotropein, deacetylaspelurosidic acid, rehmannioside D, echinacoside, cyasterone, xanthotoxol, isopimpinellin, xanthotoxin, toosendanin, 19α-hydroxyasiatic acid, rubiadin-1-methylether, schisandrin, schisandrolB, imperatorin, osthole, schisantherin A, schisantherin B, schisandrin A, cuscutamine, schisandrin B, kaempferol3-O-rutinoside, kaempferol, isochlorogenicacid C, and isoquercitrin were purchased from Chengdu Pusi Biotechnology Co., Ltd. Nystose, ginsenoside Rg2, ginsenoside Rc, ginsenoside Rb2, icariin, epimedin A, epimedin B, epimedin C, icariside I, icariside II, icaritin, betaine, magnoflorine, neochlorogenic acid, chlorogenic acid were purchased from Shanghai Ronghe Pharmaceutical Technology Co., Ltd. Hyperin, gallic acid, elagic acid, ginsenoside Rb1, γ-Glctamyl-S-allylcysteine, were purchased from Chengdu Purifa Technology Development Co., Ltd. Ferulic acid, astragalin, azelaic acid, ginsenoside Re, ginsenoside Ro, ginsenoside Rd were purchased from Chengdu Kroma Co., Ltd. Adenine, 6-hydroxypurine were purchased from Shanghai MacLean Biochemical Technology Co., Ltd. Ginsenoside Rg1, quercetin were purchased from Chengdu Efa Biological Co., Ltd. Acteoside was purchased from Anhui Zesheng Technology Co., Ltd. After HPLC identification, the purity of all reference substances was ≥98%.

[0059] Water for mass spectrometry (HPLC grade) was purchased from Beijing Watsons Distilled Water Co., Ltd.; mass spectrometry grade methanol and acetonitrile were purchased from Thermo Fisher Scientific, USA; mass spectrometry grade formic acid was purchased from Sigma Aldrich, USA; other reagents were of analytical grade and purchased from the market.

[0060] The raw materials and reagents used in the quantitative detection method of the ingredients of the Bazi Bushen Capsule provided by the present invention can all be purchased from the market.

[0061] The present invention will be further described below in conjunction with embodiments:

[0062] Example 1 Preparation of standard solution

[0063] 17 compounds (Hyperin, Osthole, Imperatorin, Isopimpinellin, Xanthotoxin, Icaritin, Icariin, Epimedin C, Magnoflorine, Rutin, Schisantherin B, Schisandrin, Schisantherin A, Schisandrin B, 19α-Hydroxyasiatic A) were accurately weighed.

[0064] 19α-Hydroxyasiatic acid, cariside II, and Cuscutamine) were dissolved in methanol to prepare standard solutions with a concentration of 100 μg / ml. These solutions were then diluted with methanol into a 10 mL volumetric flask to obtain mixed standard solutions of different concentrations. Accurately weigh 0.5 g of the contents of the Bazi Bushen Capsule, and ultrasonically extract with 70% methanol for 30 minutes to obtain an extract with a concentration of 100 μg / mL. Prepare other batches of samples in the same way. The above extract was then centrifuged at 13200 rpm for 10 minutes. Finally, the supernatant was taken for UPLC-QQQ-MS analysis.

[0065] Example 2 UPLC-QQQ-MS liquid mass analysis conditions

[0066] The system was separated by a Waters Acquity UPLC I-Class system (Waters, Milford, MA, USA), using an Acquity UPLC HSS T3 column (2.1×50 mm, 1.8 μm, Waters, Milford, USA) at 35°C. The mobile phase was 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile (B) at a flow rate of 0.3 mL / min. The gradient elution program was run as follows: 0-2.5 min, 2-15% B; 2.5-6.5 min, 15-36% B; 6.5-12.5 min, 36-75% B; 12.5-14 min, 75-100% B; 14-15 min, 100% 15-16 min, 100%-2% B; 16-17 min, 2% B.

[0067] Mass spectrometry was performed on a Xevo triple quadrupole mass spectrometer (Waters, Milford, MA, USA) equipped with an ESI source and run using Masslynx4.2 software (Waters, Milford, MA, USA). The optimized mass spectrometry parameters were as follows: capillary voltages were 2.0 kV (ESI+) and 2.0 kV (ESI-), respectively; ion source temperature was 150 °C, desolvation temperature was 550 °C, desolvation gas flow rate was 1000 L / h, and cone backflush gas flow rate was 150 L / h. Multiple reaction monitoring (MRM) was used for detection in positive and negative ion modes. The ion pairs, cone voltages, and collision energies are shown in Table 1.

[0068] Table 1. MRM parameters for the determination of 17 components in Bazibushen Capsule

[0069]

[0070] Example 3 Results of Methodological Validation of Content Determination of Bazi Bushen Capsules - Specificity Investigation

[0071] The test solution of Bazi Bushen Capsule (batch: A2201001), mixed reference solution and blank solvent were taken for testing respectively.

[0072] The results are as follows Figure 1 to Figure 17 As shown, there are no interfering peaks in the blank solvent at the corresponding positions of the chromatographic peaks of each quantitative component in the reference substance spectrum; the chromatographic peaks of the above 17 quantitative components appear in the test solution at the corresponding positions of the mixed reference substance spectrum, and the method has good specificity.

[0073] Example 4 Results of Methodological Validation of Content Determination of Bazi Bushen Capsules - Linearity and Range Investigation

[0074] Linear regression analysis was performed with the peak area as the ordinate and the concentration of each reference substance as the abscissa to obtain the linear regression equation and correlation coefficient of each quantitative component (Table 2). At the same time, the mixed reference substance solution was diluted in multiples and then injected for analysis. When the signal-to-noise ratio S / N of the component to be tested was ≥10, it was recorded as the quantitative limit of the compound (Table 2).

[0075] Table 2. Linearity, range and quantification limit of 17 quantitative components in Bazi Bushen Capsule

[0076]

[0077] The results showed that the quantitative components had good linearity within the linear range (R 2 >0.996), which meets the analytical test requirements.

[0078] Example 5 Results of Methodological Validation of Content Determination of Bazi Bushen Capsules - Repeatability Study

[0079] Take 0.5 g of the same batch of Bazi Bushen Capsule samples (batch: A2201001), accurately weigh them, and make six parallel copies. Record and count the peak areas of 17 quantitative components and calculate the contents and RSD values.

[0080] Table 3. Results of repeatability test of 17 quantitative components in Bazi Bushen Capsule (n=6) (μg / g)

[0081]

[0082]

[0083] The results are shown in Table 3. The RSD of the 17 quantitative components was ≤4.9%. The method had good repeatability and met the analytical test requirements.

[0084] Example 6 Results of Methodological Validation of Content Determination of Bazi Bushen Capsules - Inter-day and Intra-day Precision Investigation

[0085] 0.5 g of the same batch of Bazi Bushen Capsule samples (batch: A2201001) were taken, accurately weighed, and measured in triplicate for three consecutive days. The peak areas of 17 quantitative components were recorded and counted, and the contents and RSD values ​​were calculated.

[0086] Table 4. Intermediate precision test results of 17 quantitative components of Bazi Bushen Capsule (n=3) (μg / g)

[0087]

[0088]

[0089] The results are shown in Table 4. The RSD of the 17 quantitative components was ≤3.8%. The intra-day and inter-day precision of this method was good and met the analytical test requirements.

[0090] Example 7 Results of Methodological Verification of Content Determination of Bazi Bushen Capsules - Accuracy Investigation

[0091] Take 0.5g of the same batch of Bazi Bushen Capsule samples (batch: A2201001), accurately weigh, and parallel six times, record and count the peak areas of 17 quantitative components and calculate the content and RSD value. Calculate the sample recovery rate, average recovery rate and RSD value of each quantitative component according to the following formula. Sample recovery rate (%) = (measured value - content of the measured component contained in the test solution) / amount of reference substance added * 100.

[0092] Table 5. Accuracy test results of 17 quantitative components of Bazi Bushen Capsule (n=6) (μg / g)

[0093]

[0094]

[0095]

[0096]

[0097]

[0098] The results are shown in Table 5. The recovery rates of the 17 quantitative components were within 91.7%-106.8%, and RSD≤9.0%. The results show that the method has high accuracy and meets the test requirements.

[0099] Example 8 Results of Methodological Verification of Content Determination of Bazi Bushen Capsules - Stability Study

[0100] 0.5 g of the same batch of Bazi Bushen Capsule samples (batch: A2201001) were taken and accurately weighed. Three replicates were placed at 15°C for 0, 2, 4, and 8 hours, respectively, for measurement, and the peak areas and RSD values ​​of the 17 quantitative components were recorded and counted.

[0101] Table 6. Stability test results of 17 quantitative components of Bazi Bushen Capsule (n=3)

[0102]

[0103]

[0104] The results are shown in Table 6. The RSD of the 17 quantitative components was ≤7.0%. The test solution prepared by this method was stored at 15°C and was stable within 8 hours, meeting the analytical test requirements.

[0105] Example 9 Methodological verification results of content determination of Bazi Bushen Capsules - Batch content determination results of Bazi Bushen Capsules

[0106] The UPLC-QQQ-MS method was validated for the quantitative determination of 17 components in Bazi Bushen Capsules. The method met the requirements for specificity, linearity, precision, repeatability, recovery, and stability. The linear correlation coefficients of the calibration curves of the 17 components were acceptable over a wide range, and the correlation coefficients (R 2 ) were all greater than 0.99 (external standard method). The precision, repeatability and stability of the quantitative method for 17 components were verified. The intra-day and inter-day precisions were expressed as RSDs, ranging from 0.1-2.7% and 1.5-3.8%, respectively. The repeatability and stability did not exceed 4.9% and 7.0%, respectively. Therefore, the established method has good reproducibility, precision and stability. The average recovery was 91.7%-106.8%, and the RSD was less than 9.0%. The results showed that the established method was suitable for the quantitative analysis of 17 components in Bazibushen Capsules. The contents of 17 components in 10 batches of Bazibushen Capsules were determined by UPLC-QQQ-MS. It is worth noting that the average contents of cuscutamine, epimedin C, osthole, icariin and hyperin in Bazibushen Capsules were higher than 800μg / g. The sum of these five components accounted for about 80% of the total tested components.

[0107] Table 7. Content determination results of 10 batches of Bazi Bushen Capsules (μg / g).

[0108]

[0109]

[0110] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A quantitative detection method for the ingredients of Bazi Bushen Capsule, characterized in that: The steps include: Take the contents of Bazi Bushen Capsule to prepare sample solution; Take the standard sample to prepare the standard solution; The sample solution and the standard solution were respectively taken for UPLC-QQQ-MS detection to determine the content of the ingredients in the Bazi Bushen Capsule.

2. The quantitative detection method according to claim 1, characterized in that The detection includes chromatography and mass spectrometry; The mobile phase of the chromatographic analysis includes: A is a 0.1% (v / v) formic acid solution, and B is a 0.1% (v / v) formic acid acetonitrile solution.

3. The quantitative detection method according to claim 2, characterized in that: The flow rate of the chromatography is 0.3 ml / min; and / or The injection volume of the chromatographic analysis was 2 μL.

4. The quantitative detection method according to claim 2 or 3, characterized in that: The gradient elution conditions of the chromatographic analysis are: 0-2.5min, 2-15% B; 2.5-6.5min, 15-36% B; 6.5-12.5min, 36-75% B; 12.5-14min, 75-100% B; 14-15min, 100% B; 15-16min, 100%-2% B; 16-17min 2% B.

5. The quantitative detection method according to any one of claims 2 to 4, characterized in that: The chromatographic analysis used an Acquity UPLC HSS T3 column, and the temperature of the chromatographic column was 35°C.

6. The quantitative detection method according to claim 2, characterized in that: The mass spectrometry analysis adopts an electrospray ion source, positive ion and negative ion mode detection, the acquisition method is Fast DDA, the scanning range is m / z 50-1500Da, and the capillary spray voltage ion is 2.0kV (ESI+) and 2.0kV (ESI-).

7. The quantitative detection method according to any one of claims 2 to 6, characterized in that: The source temperature of the mass spectrometry analysis was 150° C., the desolvation gas temperature was 550° C., the desolvation gas flow rate was 1000 L / h, the cone gas flow rate was 150 L / h, and the analytes were detected in positive and negative multiple reaction monitoring (MRM) modes.

8. The quantitative detection method according to any one of claims 1 to 7, characterized in that: The sample solution is prepared by dissolving the contents of the Bazi Bushen Capsule with methanol, ultrasonically extracting, centrifuging, filtering, and collecting the supernatant to obtain the sample solution; The preparation method of the standard solution is: taking the standard, dissolving and diluting it with methanol to obtain the standard solutions of different concentrations.

9. The quantitative detection method according to any one of claims 1 to 8, characterized in that: The sample solution is prepared by taking the contents of the Bazi Bushen Capsule, dissolving and extracting it with a 70% methanol solution, ultrasonically treating it for 30 minutes, centrifuging it at 13200 rpm for 10 minutes, filtering it, and collecting the supernatant.

10. The quantitative detection method according to any one of claims 1 to 8, characterized in that: The ingredients of the Ba Zi Bushen Capsule include Hyperin, Osthole, Imperatorin, Isopimpinellin, Xanthotoxin, Icaritin, Icariin, Cepimedin C, Magnoflorine, Rutin, Schisantherin B, Schisandrin, Schisantherin A, Schisandrin B, 19α-Hydroxyasiatic acid, cariside II, and Cuscutamine; The ingredient contents of the Bazi Bushen Capsule are shown in Table 7.